Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits
Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade ) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performance, agreement and clinically relevant differences of three comm...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry and laboratory medicine 2016-07, Vol.54 (7), p.1211-1219 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1219 |
|---|---|
| container_issue | 7 |
| container_start_page | 1211 |
| container_title | Clinical chemistry and laboratory medicine |
| container_volume | 54 |
| creator | Schmitz, Ellen M.H. van de Kerkhof, Daan Hamann, Dörte van Dongen, Joost L.J. Kuijper, Philip H.M. Brunsveld, Luc Scharnhorst, Volkher Broeren, Maarten A.C. |
| description | Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade
) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performance, agreement and clinically relevant differences of three commercially available IFX ELISA kits on an automated processing system.
The kits of Theradiag (Lisa Tracker Infliximab), Progenika (Promonitor IFX) and apDia (Infliximab ELISA) were implemented on an automated processing system. Imprecision was determined by triplicate measurements of patient samples on five days. Agreement was evaluated by analysis of 30 patient samples and four spiked samples by the selected ELISA kits and the in-house IFX ELISA of Sanquin Diagnostics (Amsterdam, The Netherlands). Therapeutic consequences were evaluated by dividing patients into four treatment groups using cut-off levels of 1, 3 and 7 μg/mL and determining assay concordance.
Within-run and between-run imprecision were acceptable (≤12% and ≤17%, respectively) within the quantification range of the selected ELISA kits. The apDia assay had the best precision and agreement to target values. Statistically significant differences were found between all assays except between Sanquin Diagnostics and the Lisa Tracker assay. The Promonitor assay measured the lowest IFX concentrations, the apDia assay the highest. When patients were classified in four treatment categories, 70% concordance was achieved.
Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization. |
| doi_str_mv | 10.1515/cclm-2015-0987 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1794122863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1794122863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-92360d4c8a1f2eb3c1c2d73aa2db2f3bce2e504d22963c3ff9541a6b090936163</originalsourceid><addsrcrecordid>eNp1kTFv2zAQRomiReM6WTsWHLso5ZEUZQXIYBhOa8BAhiYzQ1FHh6kkOqSU1P8-Up10y3Tf8O4D7h0hX4GdQw75D2ubNuMM8oyVi-IDmYEURSaFgI__ssyU4nBCvqT0wEYsl8VncsJVvigKmc_I3c09RrPHofeW1nHY0TZ0vg_RdzsaHPWda_xf35rqgu4xuhBb01mk-GSawfQ-dBPV30dEakPbYrTeNHS93fxe0j--T6fkkzNNwrPXOSe3V-ub1a9se_1zs1puMytk2WclF4rV0i4MOI6VsGB5XQhjeF1xJyqLHHMma85LJaxwrswlGFWxkpVCgRJz8v3Yu4_hccDU69Yni01jOgxD0lCUEjhfKDGi50fUxpBSRKf3cbwwHjQwPVnVk1U9WdWT1XHh22v3ULVY_8ffNI7A5RF4Nk2PscZdHA5j0A9hiN149jvN4zeAA4gXVjmIDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1794122863</pqid></control><display><type>article</type><title>Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits</title><source>MEDLINE</source><source>De Gruyter journals</source><creator>Schmitz, Ellen M.H. ; van de Kerkhof, Daan ; Hamann, Dörte ; van Dongen, Joost L.J. ; Kuijper, Philip H.M. ; Brunsveld, Luc ; Scharnhorst, Volkher ; Broeren, Maarten A.C.</creator><creatorcontrib>Schmitz, Ellen M.H. ; van de Kerkhof, Daan ; Hamann, Dörte ; van Dongen, Joost L.J. ; Kuijper, Philip H.M. ; Brunsveld, Luc ; Scharnhorst, Volkher ; Broeren, Maarten A.C.</creatorcontrib><description>Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade
) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performance, agreement and clinically relevant differences of three commercially available IFX ELISA kits on an automated processing system.
The kits of Theradiag (Lisa Tracker Infliximab), Progenika (Promonitor IFX) and apDia (Infliximab ELISA) were implemented on an automated processing system. Imprecision was determined by triplicate measurements of patient samples on five days. Agreement was evaluated by analysis of 30 patient samples and four spiked samples by the selected ELISA kits and the in-house IFX ELISA of Sanquin Diagnostics (Amsterdam, The Netherlands). Therapeutic consequences were evaluated by dividing patients into four treatment groups using cut-off levels of 1, 3 and 7 μg/mL and determining assay concordance.
Within-run and between-run imprecision were acceptable (≤12% and ≤17%, respectively) within the quantification range of the selected ELISA kits. The apDia assay had the best precision and agreement to target values. Statistically significant differences were found between all assays except between Sanquin Diagnostics and the Lisa Tracker assay. The Promonitor assay measured the lowest IFX concentrations, the apDia assay the highest. When patients were classified in four treatment categories, 70% concordance was achieved.
Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/cclm-2015-0987</identifier><identifier>PMID: 26587745</identifier><language>eng</language><publisher>Germany: De Gruyter</publisher><subject>assay comparison ; Drug Monitoring - methods ; ELISA ; Enzyme-Linked Immunosorbent Assay - methods ; Gastrointestinal Agents - blood ; Humans ; Infliximab ; Infliximab - blood ; Netherlands ; Predictive Value of Tests ; Reagent Kits, Diagnostic ; therapeutic drug monitoring</subject><ispartof>Clinical chemistry and laboratory medicine, 2016-07, Vol.54 (7), p.1211-1219</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-92360d4c8a1f2eb3c1c2d73aa2db2f3bce2e504d22963c3ff9541a6b090936163</citedby><cites>FETCH-LOGICAL-c349t-92360d4c8a1f2eb3c1c2d73aa2db2f3bce2e504d22963c3ff9541a6b090936163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2015-0987/pdf$$EPDF$$P50$$Gwalterdegruyter$$H</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2015-0987/html$$EHTML$$P50$$Gwalterdegruyter$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,66497,68281</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26587745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmitz, Ellen M.H.</creatorcontrib><creatorcontrib>van de Kerkhof, Daan</creatorcontrib><creatorcontrib>Hamann, Dörte</creatorcontrib><creatorcontrib>van Dongen, Joost L.J.</creatorcontrib><creatorcontrib>Kuijper, Philip H.M.</creatorcontrib><creatorcontrib>Brunsveld, Luc</creatorcontrib><creatorcontrib>Scharnhorst, Volkher</creatorcontrib><creatorcontrib>Broeren, Maarten A.C.</creatorcontrib><title>Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clin Chem Lab Med</addtitle><description>Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade
) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performance, agreement and clinically relevant differences of three commercially available IFX ELISA kits on an automated processing system.
The kits of Theradiag (Lisa Tracker Infliximab), Progenika (Promonitor IFX) and apDia (Infliximab ELISA) were implemented on an automated processing system. Imprecision was determined by triplicate measurements of patient samples on five days. Agreement was evaluated by analysis of 30 patient samples and four spiked samples by the selected ELISA kits and the in-house IFX ELISA of Sanquin Diagnostics (Amsterdam, The Netherlands). Therapeutic consequences were evaluated by dividing patients into four treatment groups using cut-off levels of 1, 3 and 7 μg/mL and determining assay concordance.
Within-run and between-run imprecision were acceptable (≤12% and ≤17%, respectively) within the quantification range of the selected ELISA kits. The apDia assay had the best precision and agreement to target values. Statistically significant differences were found between all assays except between Sanquin Diagnostics and the Lisa Tracker assay. The Promonitor assay measured the lowest IFX concentrations, the apDia assay the highest. When patients were classified in four treatment categories, 70% concordance was achieved.
Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization.</description><subject>assay comparison</subject><subject>Drug Monitoring - methods</subject><subject>ELISA</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Gastrointestinal Agents - blood</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Infliximab - blood</subject><subject>Netherlands</subject><subject>Predictive Value of Tests</subject><subject>Reagent Kits, Diagnostic</subject><subject>therapeutic drug monitoring</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kTFv2zAQRomiReM6WTsWHLso5ZEUZQXIYBhOa8BAhiYzQ1FHh6kkOqSU1P8-Up10y3Tf8O4D7h0hX4GdQw75D2ubNuMM8oyVi-IDmYEURSaFgI__ssyU4nBCvqT0wEYsl8VncsJVvigKmc_I3c09RrPHofeW1nHY0TZ0vg_RdzsaHPWda_xf35rqgu4xuhBb01mk-GSawfQ-dBPV30dEakPbYrTeNHS93fxe0j--T6fkkzNNwrPXOSe3V-ub1a9se_1zs1puMytk2WclF4rV0i4MOI6VsGB5XQhjeF1xJyqLHHMma85LJaxwrswlGFWxkpVCgRJz8v3Yu4_hccDU69Yni01jOgxD0lCUEjhfKDGi50fUxpBSRKf3cbwwHjQwPVnVk1U9WdWT1XHh22v3ULVY_8ffNI7A5RF4Nk2PscZdHA5j0A9hiN149jvN4zeAA4gXVjmIDw</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Schmitz, Ellen M.H.</creator><creator>van de Kerkhof, Daan</creator><creator>Hamann, Dörte</creator><creator>van Dongen, Joost L.J.</creator><creator>Kuijper, Philip H.M.</creator><creator>Brunsveld, Luc</creator><creator>Scharnhorst, Volkher</creator><creator>Broeren, Maarten A.C.</creator><general>De Gruyter</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160701</creationdate><title>Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits</title><author>Schmitz, Ellen M.H. ; van de Kerkhof, Daan ; Hamann, Dörte ; van Dongen, Joost L.J. ; Kuijper, Philip H.M. ; Brunsveld, Luc ; Scharnhorst, Volkher ; Broeren, Maarten A.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-92360d4c8a1f2eb3c1c2d73aa2db2f3bce2e504d22963c3ff9541a6b090936163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>assay comparison</topic><topic>Drug Monitoring - methods</topic><topic>ELISA</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Gastrointestinal Agents - blood</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Infliximab - blood</topic><topic>Netherlands</topic><topic>Predictive Value of Tests</topic><topic>Reagent Kits, Diagnostic</topic><topic>therapeutic drug monitoring</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmitz, Ellen M.H.</creatorcontrib><creatorcontrib>van de Kerkhof, Daan</creatorcontrib><creatorcontrib>Hamann, Dörte</creatorcontrib><creatorcontrib>van Dongen, Joost L.J.</creatorcontrib><creatorcontrib>Kuijper, Philip H.M.</creatorcontrib><creatorcontrib>Brunsveld, Luc</creatorcontrib><creatorcontrib>Scharnhorst, Volkher</creatorcontrib><creatorcontrib>Broeren, Maarten A.C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmitz, Ellen M.H.</au><au>van de Kerkhof, Daan</au><au>Hamann, Dörte</au><au>van Dongen, Joost L.J.</au><au>Kuijper, Philip H.M.</au><au>Brunsveld, Luc</au><au>Scharnhorst, Volkher</au><au>Broeren, Maarten A.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clin Chem Lab Med</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>54</volume><issue>7</issue><spage>1211</spage><epage>1219</epage><pages>1211-1219</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>Therapeutic drug monitoring (TDM) of infliximab (IFX, Remicade
) can aid to optimize therapy efficacy. Many assays are available for this purpose. However, a reference standard is lacking. Therefore, we evaluated the analytical performance, agreement and clinically relevant differences of three commercially available IFX ELISA kits on an automated processing system.
The kits of Theradiag (Lisa Tracker Infliximab), Progenika (Promonitor IFX) and apDia (Infliximab ELISA) were implemented on an automated processing system. Imprecision was determined by triplicate measurements of patient samples on five days. Agreement was evaluated by analysis of 30 patient samples and four spiked samples by the selected ELISA kits and the in-house IFX ELISA of Sanquin Diagnostics (Amsterdam, The Netherlands). Therapeutic consequences were evaluated by dividing patients into four treatment groups using cut-off levels of 1, 3 and 7 μg/mL and determining assay concordance.
Within-run and between-run imprecision were acceptable (≤12% and ≤17%, respectively) within the quantification range of the selected ELISA kits. The apDia assay had the best precision and agreement to target values. Statistically significant differences were found between all assays except between Sanquin Diagnostics and the Lisa Tracker assay. The Promonitor assay measured the lowest IFX concentrations, the apDia assay the highest. When patients were classified in four treatment categories, 70% concordance was achieved.
Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization.</abstract><cop>Germany</cop><pub>De Gruyter</pub><pmid>26587745</pmid><doi>10.1515/cclm-2015-0987</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1434-6621 |
| ispartof | Clinical chemistry and laboratory medicine, 2016-07, Vol.54 (7), p.1211-1219 |
| issn | 1434-6621 1437-4331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1794122863 |
| source | MEDLINE; De Gruyter journals |
| subjects | assay comparison Drug Monitoring - methods ELISA Enzyme-Linked Immunosorbent Assay - methods Gastrointestinal Agents - blood Humans Infliximab Infliximab - blood Netherlands Predictive Value of Tests Reagent Kits, Diagnostic therapeutic drug monitoring |
| title | Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A13%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20drug%20monitoring%20of%20infliximab:%20performance%20evaluation%20of%20three%20commercial%20ELISA%20kits&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=Schmitz,%20Ellen%20M.H.&rft.date=2016-07-01&rft.volume=54&rft.issue=7&rft.spage=1211&rft.epage=1219&rft.pages=1211-1219&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/cclm-2015-0987&rft_dat=%3Cproquest_cross%3E1794122863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1794122863&rft_id=info:pmid/26587745&rfr_iscdi=true |